Pharmaceutical Technology1 小时
Risk adjusted net present value: What is the current valuation of Oncolytics Biotech’s ...
Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).